#HighQs 2018: First cannabis drug approved” graphic showing an Epidiolex oral solution bottle on a medical counter, with Pot Culture Magazine logo and PotCultureMagazine.com visible.

#HighQs: In 2018, the FDA approved Epidiolex, a cannabis derived medication, marking the first time a drug derived from marijuana received federal approval in the U.S. #PotCultureMagazine #CannabisScience #MedicalCannabis #CannabisCulture #Epidiolex #420Community #Medication

Jazz Pharmaceuticals to Showcase Innovations in Neurology at AAN Annual Meeting At the upcoming 2026 AAN Annual Meeting, Jazz Pharmaceuticals will present significant research on Epidiolex and Xywav, targeting rare neurological disorders.

Jazz Pharmaceuticals to Showcase Innovations in Neurology at AAN Annual Meeting #United_States #Chicago #Jazz_Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Reports Strong Financial Performance for 2025 and Projects Growth for 2026 Jazz Pharmaceuticals has announced a remarkable financial performance in 2025, with $4.3 billion in total revenue. The company anticipates continued growth in 2026 supported by robust new product launches.

Jazz Pharmaceuticals Reports Strong Financial Performance for 2025 and Projects Growth for 2026 #USA #Dublin #Jazz_Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Unveils New Research at 2025 American Epilepsy Society Meeting Jazz Pharmaceuticals showcased new data on Epidiolex® at the AES 2025 Annual Meeting, emphasizing its impact on treatment-resistant epilepsies.

Jazz Pharmaceuticals Unveils New Research at 2025 American Epilepsy Society Meeting #United_States #Atlanta #Jazz_Pharmaceuticals #Epidiolex #AES_2025

‘Will of the People’: Love, epilepsy, and medical cannabis for an Omaha boy Teddy lives with DUP15Q, a genetic chromosome disorder without a cure.

"One of his current medications, an FDA approved cannabinoid called Epidiolex, costs about $3,200 a box. Each month, the Bronson family bills an extra $21,000 to pay for it."
#MedicalMarijuana #MedicalCannabis #Marijuana #Cannabis #Epilepsy #Seizures #Cannabinoid #Epidiolex

Jazz Pharmaceuticals Reports Strong Third Quarter 2025 Results and Inspirational Updates on Financial Guidance Jazz Pharmaceuticals has announced robust financial results for the third quarter of 2025, showcasing a 7% revenue increase and significant product launches.

Jazz Pharmaceuticals Reports Strong Third Quarter 2025 Results and Inspirational Updates on Financial Guidance #USA #Dublin #Jazz_Pharmaceuticals #Epidiolex #Modeyso

Jazz Pharmaceuticals Reports Impressive Q3 2025 Financial Results and Updates 2025 Outlook Jazz Pharmaceuticals has revealed its third-quarter financial results for 2025, showcasing substantial revenue growth and strategic updates for the future.

Jazz Pharmaceuticals Reports Impressive Q3 2025 Financial Results and Updates 2025 Outlook #USA #Dublin #Jazz_Pharmaceuticals #Epidiolex #Modeyso

FDA-Approved CBD Associated With Behavior Improvements in Autistic Boys Clinical trial results showed "reductions in aggressive behaviors and hyperactivity"

🌿 "Blinded clinical impressions showed almost two-third of the participants had behavioral improvements with CBD," researchers reported. #NORML #cannabis #marijuana #CBD #autism #Epidiolex

FDA-Approved CBD Formulation Significantly Reduces Seizure Frequency 49% of patients experienced a greater than 25% reduction

​​🌿 Nearly half of pediatric patients prescribed #CBD in the form of #Epidiolex achieve a ≤25 percent reduction in seizures, according to clinical trial data published in the journal #Epilepsy & Behavior. #NORML #cannabis #marijuana

Jazz Pharmaceuticals Reports First Quarter 2025 Financial Results and Adjustments to Future Guidance Discover the latest financial performance and updates from Jazz Pharmaceuticals for the first quarter of 2025, revealing trends and future plans.

Jazz Pharmaceuticals Reports First Quarter 2025 Financial Results and Adjustments to Future Guidance #United_States #Dublin #Jazz_Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Reports Strong Q1 2025 Financial Results and Updates Guidance for the Year Ahead Jazz Pharmaceuticals PLC demonstrates resilience with $898M in revenues for Q1 2025, driven by growth in key products. The company updates its financial outlook reflecting positive business trends.

Jazz Pharmaceuticals Reports Strong Q1 2025 Financial Results and Updates Guidance for the Year Ahead #USA #Dublin #Jazz_Pharmaceuticals #Epidiolex #Xywav

EPIDIOLEX: Revolutionizing Epilepsy Treatment Through Cannabinoid Innovation EPIDIOLEX stands at the forefront of epilepsy treatment, leveraging CBD's unique properties to manage rare seizure disorders. Discover its profound market impact and evolving role.

EPIDIOLEX: Revolutionizing Epilepsy Treatment Through Cannabinoid Innovation #United_States #Las_Vegas #Cannabinoids #Epidiolex #CBD

Jazz Pharmaceuticals Presents Innovative Research on Xywav® and Epidiolex® at AAN Annual Meeting Jazz Pharmaceuticals reveals significant findings on Xywav® and Epidiolex®, showcasing their commitment to addressing neurological disorders at the 2025 AAN Annual Meeting.

Jazz Pharmaceuticals Presents Innovative Research on Xywav® and Epidiolex® at AAN Annual Meeting #Ireland #Dublin #Jazz_Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Unveils Strong Financial Performance for 2024 and 2025 Outlook Jazz Pharmaceuticals has announced impressive fourth-quarter and full-year financial results for 2024, highlighting significant revenue growth and promising projections for 2025.

Jazz Pharmaceuticals Unveils Strong Financial Performance for 2024 and 2025 Outlook #Ireland #Dublin #Jazz_Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Presents New Real-World Data Supporting the Efficacy of Epidiolex in Epilepsy Treatment at AES 2024 At the American Epilepsy Society 2024 Annual Meeting, Jazz Pharmaceuticals unveiled significant real-world evidence backing Epidiolex's benefits in epilepsy treatment.

Jazz Pharmaceuticals Presents New Real-World Data Supporting the Efficacy of Epidiolex in Epilepsy Treatment at AES 2024 #United_States #Los_Angeles #Epilepsy #Jazz_Pharmaceuticals #Epidiolex

Seizures have definitely exponentially decreased since I started taking #Epidiolex but I am still having breakthrough seizures about twice a week. #disabled #epileptic #spaz